5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.

Full Abstract

Genes that regulate the serotonin signalling system are potential targets for research in the aetiology of mood disorders and also in the treatment response of serotonin reuptake inhibitors. In this study, we evaluated the association of seven serotonin signal transduction-linked single nucleotide polymorphisms [HTR1A (rs6295), HTR2A (rs6313, rs6311 and rs7997012), HTR6 (rs1805054), TPH1 (rs1800532) and TPH2 (rs1386494)] with major depressive disorder and/or treatment outcome with serotonin reuptake inhibitors. Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram. The treatment response was evaluated with the Montgomery-Asberg Depression Rating Scale, and according to predefined response criteria, the patients were divided into responders, nonresponders, remitters and nonremitters. Altogether, 86 patients completed the entire study according to the study protocol. We had also a control population (N = 395) of healthy blood donors. None of the seven single nucleotide polymorphisms was associated with major depressive disorder or with treatment response in our study population of Finnish individuals.

Author information

Author/s: Illi, Ari (A); Setälä-Soikkeli, Eija (E); Viikki, Merja (M); Poutanen, Outi (O); Huhtala, Heini (H); Mononen, Nina (N); Lehtimäki, Terho (T); Leinonen, Esa (E); Kampman, Olli (O);

Affiliation: University of Tampere, Medical School, Tampere, Finland. ari.illi(-atsign-)uta.fi

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Neuroreport (Neuroreport), published in England. (Language: eng)

Reference: 2009-Aug; vol 20 (issue 12) : pp 1125-8

Dates: Created 2009/07/10; Completed 2009/09/29;

PMID: 19590397, status: MEDLINE (last retrieval date: 9/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent
Adult
Aged
Citalopram - therapeutic use
Depressive Disorder, Major - drug therapy; genetics
Fluoxetine - therapeutic use
Humans
Middle Aged
Paroxetine - therapeutic use

Associated Chemicals: Receptor, Serotonin, 5-HT2A (0) ; Receptors, Serotonin (0) ; Serotonin Uptake Inhibitors (0) ; serotonin 6 receptor (0) ; Receptor, Serotonin, 5-HT1A (112692-38-3) ; Fluoxetine (54910-89-3) ; Citalopram (59729-33-8) ; Paroxetine (61869-08-7) ; TPH1 protein, human (EC 1.14.16.4) ; TPH2 protein, human (EC 1.14.16.4) ; Tryptophan Hydroxylase (EC 1.14.16.4)

These are the highest related articles currently in the database: